Unknown

Dataset Information

0

Quantitative proteomic (iTRAQ) analysis of 1st trimester maternal plasma samples in pregnancies at risk for preeclampsia.


ABSTRACT: A current major obstacle is that no reliable screening markers exist to detect pregnancies at risk for preeclampsia. Quantitative proteomic analysis employing isobaric labelling (iTRAQ) has been suggested to be suitable for the detection of potential plasma biomarkers, a feature we recently verified in analysis of pregnancies with Down syndrome foetuses. We have now examined whether this approach could yield biomarkers to screen pregnancies at risk for preeclampsia. In our study, we used maternal plasma samples obtained at 12 weeks of gestation, six from women who subsequently developed preeclampsia and six with uncomplicated deliveries. In our analysis, we observed elevations in 10 proteins out of 64 proteins in the preeclampsia study group when compared to the healthy control group. These proteins included clusterin, fibrinogen, fibronectin, and angiotensinogen, increased levels of which are known to be associated with preeclampsia. An elevation in the immune-modulatory molecule, galectin 3 binding protein, was also noted. Our pilot study, therefore, indicates that quantitative proteomic iTRAQ analysis could be a useful tool for the detection of new preeclampsia screening markers.

SUBMITTER: Kolla V 

PROVIDER: S-EPMC3335425 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature

altmetric image

Publications

Quantitative proteomic (iTRAQ) analysis of 1st trimester maternal plasma samples in pregnancies at risk for preeclampsia.

Kolla Varaprasad V   Jenö Paul P   Moes Suzette S   Lapaire Olav O   Hoesli Irene I   Hahn Sinuhe S  

Journal of biomedicine & biotechnology 20120410


A current major obstacle is that no reliable screening markers exist to detect pregnancies at risk for preeclampsia. Quantitative proteomic analysis employing isobaric labelling (iTRAQ) has been suggested to be suitable for the detection of potential plasma biomarkers, a feature we recently verified in analysis of pregnancies with Down syndrome foetuses. We have now examined whether this approach could yield biomarkers to screen pregnancies at risk for preeclampsia. In our study, we used materna  ...[more]

Similar Datasets

| S-EPMC2774473 | biostudies-literature
| S-EPMC4016723 | biostudies-literature
2015-03-31 | GSE66210 | GEO
| S-EPMC6133416 | biostudies-literature
| S-EPMC116571 | biostudies-literature
| S-EPMC3390908 | biostudies-other
| S-EPMC1899436 | biostudies-literature
2015-03-31 | E-GEOD-66210 | biostudies-arrayexpress
| S-EPMC7076905 | biostudies-literature
| S-EPMC7236207 | biostudies-literature